Stock Analysis

BrainCool Full Year 2024 Earnings: kr0.17 loss per share (vs kr0.37 loss in FY 2023)

OM:BRAIN
Source: Shutterstock

BrainCool (STO:BRAIN) Full Year 2024 Results

Key Financial Results

  • Revenue: kr44.8m (up 63% from FY 2023).
  • Net loss: kr44.0m (loss narrowed by 28% from FY 2023).
  • kr0.17 loss per share (improved from kr0.37 loss in FY 2023).
earnings-and-revenue-history
OM:BRAIN Earnings and Revenue History February 14th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

BrainCool shares are up 3.5% from a week ago.

Risk Analysis

We should say that we've discovered 5 warning signs for BrainCool (3 are significant!) that you should be aware of before investing here.

Valuation is complex, but we're here to simplify it.

Discover if BrainCool might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About OM:BRAIN

BrainCool

A medical device company, together with its subsidiaries, engages in the development, marketing, and sale of medical cooling systems for the healthcare sector in Sweden.

Moderate with adequate balance sheet.

Similar Companies